Related Experiment Video
Updated: Jun 2, 2026

Two Techniques to Create Hypoparathyroid Mice: Parathyroidectomy Using GFP Glands and Diphtheria-Toxin-Mediated Parathyroid Ablation
Published on: March 14, 2017
Benign familial hypocalciuric hypercalcemia
Jeena Varghese1, Thereasa Rich, Camilo Jimenez
1Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Insights
Benign familial hypocalciuric hypercalcemia, caused by CASR gene mutations, presents lifelong hypercalcemia. Early diagnosis is crucial to avoid unnecessary parathyroidectomy and manage this benign condition effectively.
Area of Science:
- Endocrinology
- Genetics
- Calcium Metabolism
Background:
- Benign familial hypocalciuric hypercalcemia (BFHH) is a genetic disorder causing lifelong hypercalcemia.
- It is often mistaken for primary hyperparathyroidism, leading to potential misdiagnosis and inappropriate treatment.
- The condition stems from mutations in the calcium-sensing receptor gene (CASR).
Purpose of the Study:
- To review the pathophysiology, clinical features, diagnosis, and management of BFHH.
- To differentiate BFHH from primary hyperparathyroidism.
- To emphasize the importance of avoiding surgical intervention in BFHH patients.
Main Methods:
- Systematic literature review of available studies on BFHH.
- Analysis of genetic causes, clinical presentation, and diagnostic criteria.
- Evaluation of management strategies and patient outcomes.
Main Results:
- BFHH is an autosomal dominant condition with lifelong hypercalcemia, relative hypocalciuria, and elevated parathyroid hormone.
- CASR gene loss-of-function mutations are the underlying cause.
- Complications like osteopenia and nephrolithiasis are not increased in BFHH, and parathyroidectomy is not recommended.
Conclusions:
- BFHH is an important, though uncommon, cause of hypercalcemia, particularly in younger individuals.
- Diagnosis is critical to prevent unnecessary parathyroidectomy, as hypercalcemia persists post-surgery.
- Genetic screening and family member evaluation are essential for proper management and patient counseling.
Objective:
To review the pathophysiology, clinical features, diagnosis, and management options for benign familial hypocalciuric hypercalcemia.
Methods:
We present a systematic summary of benign familial hypocalciuric hypercalcemia after review of the current available literature.
Results:
Benign familial hypocalciuric hypercalcemia is an autosomal dominant condition characterized by lifelong hypercalcemia, relative hypocalciuria, and inappropriately elevated parathyroid hormone. It is caused by a loss-of-function mutation in the calcium-sensing receptor gene (CASR). Benign familial hypocalciuric hypercalcemia is important clinically because it can be difficult to distinguish from primary hyperparathyroidism. It is a benign condition, and affected patients should be advised against parathyroidectomy. The incidence of complications associated with primary hyperparathyroidism, like osteopenia and nephrolithiasis, is not increased in persons with benign familial hypocalciuric hypercalcemia, and the rates are similar to those in the general population. Rarely, a severe form of this disease, namely neonatal severe primary hyperparathyroidism is seen in infants with homozygous CASR mutations.
Conclusions:
Benign familial hypocalciuric hypercalcemia is a small but important cause of hypercalcemia, especially in the younger population. Hypercalcemia persists after subtotal parathyroidectomy. It is important to diagnose this condition, not only in the index case but also in family members, because these patients should be advised against surgical intervention.
Related Concept Videos
Urinary Tract Calculi II: Pathophysiology and Clinical Manifestations
Synthesis and Functions of Calcitonin
The exact mechanisms by which calcitonin operates in calcium homeostasis remain elusive, but its significance is evident in several vital...
Urinary Tract Calculi I: Introduction
Skeleton and Calcium Homeostasis
Antihypertensive Drugs: Potassium-Sparing Diuretics
Huntington Disease l: Introduction
